Connor Clark & Lunn Investment Management Ltd. Raises Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 51.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 222,934 shares of the biopharmaceutical company’s stock after buying an additional 75,807 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.08% of Amicus Therapeutics worth $2,381,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. bought a new stake in shares of Amicus Therapeutics during the 2nd quarter valued at $8,386,000. M&G Plc increased its stake in Amicus Therapeutics by 12.4% in the 2nd quarter. M&G Plc now owns 748,451 shares of the biopharmaceutical company’s stock worth $7,485,000 after acquiring an additional 82,728 shares during the last quarter. CANADA LIFE ASSURANCE Co raised its stake in Amicus Therapeutics by 7.8% during the first quarter. CANADA LIFE ASSURANCE Co now owns 100,538 shares of the biopharmaceutical company’s stock valued at $1,183,000 after purchasing an additional 7,304 shares in the last quarter. Fiera Capital Corp lifted its holdings in shares of Amicus Therapeutics by 1.1% in the 2nd quarter. Fiera Capital Corp now owns 5,280,442 shares of the biopharmaceutical company’s stock valued at $52,382,000 after acquiring an additional 58,113 shares during the last quarter. Finally, Mutual of America Capital Management LLC boosted its holdings in shares of Amicus Therapeutics by 24.2% in the 2nd quarter. Mutual of America Capital Management LLC now owns 250,293 shares of the biopharmaceutical company’s stock worth $2,483,000 after purchasing an additional 48,802 shares during the period.

Insider Transactions at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $10.60, for a total value of $79,500.00. Following the sale, the chief executive officer now owns 886,654 shares in the company, valued at approximately $9,398,532.40. This represents a 0.84 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders sold a total of 30,401 shares of company stock worth $352,038 over the last three months. 2.20% of the stock is currently owned by insiders.

Amicus Therapeutics Price Performance

Shares of FOLD opened at $9.72 on Tuesday. The company has a debt-to-equity ratio of 2.18, a current ratio of 3.15 and a quick ratio of 2.42. The company’s fifty day moving average price is $10.80 and its 200-day moving average price is $10.59. The firm has a market capitalization of $2.90 billion, a PE ratio of -28.59 and a beta of 0.68. Amicus Therapeutics, Inc. has a 1-year low of $9.02 and a 1-year high of $14.57.

Wall Street Analyst Weigh In

Several brokerages recently commented on FOLD. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, November 7th. Jefferies Financial Group assumed coverage on shares of Amicus Therapeutics in a research note on Friday, September 6th. They issued a “buy” rating and a $18.00 price objective for the company. Cantor Fitzgerald boosted their price target on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Morgan Stanley dropped their price objective on Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Finally, Bank of America upped their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, October 17th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $17.63.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.